KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLong-Term Debt IssuancesLong-Term Debt RepaymentsOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares OutstandingShares Repurchased
Ratios

Charles River Laboratories International (CRL) Leases (2019 - 2025)

Charles River Laboratories International has reported Leases over the past 7 years, most recently at $24.7 million for Q4 2025.

  • For Q4 2025, Leases fell 94.02% year-over-year to $24.7 million; the TTM value through Dec 2025 reached $24.7 million, down 94.02%, while the annual FY2025 figure was $24.7 million, 94.02% down from the prior year.
  • Leases for Q4 2025 was $24.7 million at Charles River Laboratories International, down from $374.3 million in the prior quarter.
  • Over five years, Leases peaked at $412.5 million in Q4 2024 and troughed at $24.7 million in Q4 2025.
  • A 5-year average of $298.1 million and a median of $378.7 million in 2022 define the central range for Leases.
  • Biggest five-year swings in Leases: soared 1301.98% in 2024 and later tumbled 94.02% in 2025.
  • Year by year, Leases stood at $29.4 million in 2021, then skyrocketed by 1230.85% to $391.8 million in 2022, then tumbled by 92.49% to $29.4 million in 2023, then soared by 1301.98% to $412.5 million in 2024, then tumbled by 94.02% to $24.7 million in 2025.
  • Business Quant data shows Leases for CRL at $24.7 million in Q4 2025, $374.3 million in Q3 2025, and $385.8 million in Q2 2025.